CONTEXT: An august meeting of medical societies in Brussels to debate a few interesting topics for our discerning readers | Firstly the implications of the new IVD regulations which are definitely Continue Reading
CONTEXT: Commercial announcement mirroring the developing trend in pulling together RWE data sources and analytical capabilities in response to the regulatory need for more granularity to assess the safety, health, Continue Reading
Comments – Part of the growing trend for big pharma to secure bid data sources for their own use. A move in the right direction towards ‘regulatory grade’ RWE. READ Continue Reading
Comments – Part of the EMA’s continued commitment to RWE in support of medicinal product utilisation. When you see regulators investing in infrastructure like this, you know they are serious Continue Reading
COMMENTS: Part of the growing trend for big pharma to secure bid data sources for their own use. IMPACT: A move in the right direction towards ‘regulatory grade’ RWE, READ Continue Reading
